AIPT - Precision Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.01
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.01
Open1.00
Bid0.95 x 4000
Ask1.08 x 900
Day's Range1.00 - 1.05
52 Week Range0.81 - 2.50
Volume119,693
Avg. Volume178,871
Market Cap13.532M
Beta1.00
PE Ratio (TTM)N/A
EPS (TTM)-0.89
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Precision Therapeutics Bolsters Scientific Advisory Board with the Appointment of Dr. Paul Kornblith

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has bolstered its Scientific Advisory Board with the appointment of Dr. Paul Kornblith, founder and former Chairman and CEO of Helomics Corporation. The Scientific Advisory Board was formed by Precision Therapeutics in September 2018, with Dr. Marc Malandro and Dr. Amelia Warner appointed shortly thereafter.

  • GlobeNewswire11 days ago

    Precision Therapeutics Appoints Dr. Amelia Warner to Scientific Advisory Board

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Dr. Amelia Warner of Clinical Trial Concepts has been appointed as the newest member of its Scientific Advisory Board.

  • GlobeNewswire16 days ago

    Precision Therapeutics Forms Scientific Advisory Board to Advance its Strategy in the Precision Medicine Sector

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce the formation of a new Scientific Advisory Board, with Marc Malandro appointed as its first member. The Scientific Advisory Board will be comprised of world-renowned scientific and medical experts, who will work closely with Precision Therapeutics’ senior management team to advance the company's growth strategy in the precision medicine market.

  • GlobeNewswirelast month

    Precision Therapeutics Reports Second Quarter 2018 Financial Results

    MINNEAPOLIS, Aug. 14, 2018-- Precision Therapeutics Inc., a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the three ...

  • ACCESSWIRElast month

    Skyline Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Skyline Medical, Inc. (NASDAQ: AIPT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern ...

  • GlobeNewswirelast month

    Precision Therapeutics Investee, Helomics Corporation, Announces Commercial Launch of New ‘HelomicsDiscover’ Program to Drive Forward the Next Generation of Precision Cancer Therapies

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation, which has a definitive merger agreement with AIPT, has launched its new HelomicsDiscover™ program. Offered to pharma, biopharma and diagnostic partners, HelomicsDiscover™ leverages the D-CHIP™ (“Digital Clinical Health Insights Platform”) Artificial Intelligence (“AI”) powered bioinformatics platform, together with Helomics’ TruTumor™ patient-derived tumor model, to help drive the discovery of the next generation of precision cancer therapies, providing a range of solutions from target/biomarker discovery through drug screening and clinical studies, to companion diagnostics.

  • GlobeNewswirelast month

    Precision Therapeutics Investee, Helomics Corporation, Launches Precision Oncology Insights Platform

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation, which has a definitive merger agreement with AIPT, has launched its new Precision Oncology Insights platform. This platform provides a personalized oncology roadmap for oncologists and their patients. Helomics then combines this drug response profile with other genomic and molecular data.

  • GlobeNewswirelast month

    Precision Therapeutics to Hold Business Update Conference Call on August 14, 2018

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the fiscal second quarter of 2018 on August 14, 2018 after U.S. markets close. To access the conference call, U.S.-based listeners should dial +1 (866) 548-4713 and international listeners should dial +1 (323) 794-2093. To be added to the Precision Therapeutics’ database, please email Info@MoneyInfo-llc.com with your email address.  This is solely for the use of Precision Therapeutics and will not be sold or distributed to third parties.

  • GlobeNewswire2 months ago

    Precision Therapeutics Making Rapid Progress with Both Personalized Medicine and Unique Medical Waste Disposal System

    CEOLive.TV, a news organization that highlights leading CEOs, companies, and industry experts for investors, today released its second video interview [https://ceolive.tv/precision-therapeutics-aipt-gets-european-patent/] with Dr. Carl Schwartz, CEO of Precision Therapeutics Inc (AIPT). In a previous March 2018 discussion with CEOLive.TV’s Mike Elliott, Schwartz explained that Precision Therapeutics had the potential to revolutionize the treatment of cancer through personalized medicine, while also becoming a leader in the safe disposal of medical waste fluid during hospital procedures.

  • GlobeNewswire2 months ago

    Precision Therapeutics Receives Approval of Delisting Request from German Stock Exchange

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has received confirmation from the Börse-Stuttgart Stock Exchange (the “Stuttgart Stock Exchange”) that the Stuttgart Stock Exchange will delist Precision Therapeutics’ stock, traded under the symbol “S1K1” in Germany. The Company contacted the Stuttgart Stock Exchange requesting delisting of any Precision Therapeutics securities on July 23, 2018.

  • ACCESSWIRE2 months ago

    Precision Therapeutics Merger with Helomics Corp. Accelerates Personalized Cancer Treatment Strategies

    EAGAN, MN / ACCESSWIRE / July 17, 2018 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview with Dr. Carl Schwartz, President, CEO and Director of Precision Therapeutics Inc (AIPT). As Dr. Schwartz told CEOCFO's Bud Wayne, Precision Therapeutics has become a leader in personalized treatments for cancer both through its own efforts and though its recent merger with Helomics. "Precision Therapeutics is a unique entity, with a very bright future," said Dr. Schwartz.

  • GlobeNewswire2 months ago

    Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that on July 11, 2018 the European Patent Office (“EPO”) granted European Patent No. 2948200  covering the Company’s STREAMWAY® System for automated, direct-to-drain medical fluid disposal, which is sold through the Company’s Skyline Medical division. The Company is seeking national validation of its European patent in 11 European countries, including Belgium, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Spain, Sweden and the United Kingdom.

  • GlobeNewswire3 months ago

    Precision Therapeutics Signs Definitive Merger Agreement with Helomics Holding Corporation

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that it has signed a definitive merger agreement with Helomics Holding Corporation (“Helomics”). Upon completion of the merger, Precision will increase its equity stake in Helomics from 25% to 100%. This merger will provide Precision Therapeutics with full access to Helomics’ suite of Artificial Intelligence (AI), precision diagnostic and integrated CRO capabilities, which improve patient care and advance the development of innovative clinical products and technologies for the treatment of cancers.